{"id":"dna-degradation-twice-daily","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3037898","moleculeType":"Unknown","molecularWeight":"1025.71"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DNA degradation as a therapeutic approach may work by targeting rapidly dividing cells (such as cancer cells or pathogens) that depend on intact DNA for replication. The twice-daily dosing suggests a short half-life or need for sustained exposure. The mechanism could involve nuclease activity, topoisomerase inhibition, or other DNA-damaging pathways, though the specific molecular target is unclear from the description provided.","oneSentence":"This drug promotes the degradation of DNA, likely through enzymatic or chemical mechanisms that break down genetic material.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:31:48.239Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT07483684","phase":"PHASE3","title":"A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs","status":"NOT_YET_RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2026-03","conditions":"HER2 IHC3+ Advanced Colorectal Cancer","enrollment":142},{"nctId":"NCT07095361","phase":"PHASE4","title":"Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema","status":"NOT_YET_RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2025-09","conditions":"Pleural Infection Bacterial, Pleural Infections, Pleural Infections and Inflammations","enrollment":270},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT04076761","phase":"PHASE2","title":"Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma","status":"TERMINATED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2019-12-11","conditions":"Cholangiocarcinoma, Bile Duct Cancer","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":538,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["lytics twice daily","DNase twice daily"],"phase":"marketed","status":"active","brandName":"DNA degradation twice daily","genericName":"DNA degradation twice daily","companyName":"University of North Carolina, Chapel Hill","companyId":"university-of-north-carolina-chapel-hill","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}